Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.68 |
| ▸ | NQO2 | P16083 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495378 | 0.89 | MTNR1A (0.67) | MTNR1APTPN1 | |
| SCHEMBL4036596 | 0.86 | MTNR1A (0.69) | MTNR1ANQO2PTPN1 | |
| SCHEMBL31036088 | 0.85 | MTNR1A (0.65) | MTNR1A | |
| SCHEMBL29941181 | 0.84 | MTNR1A (0.73) | MTNR1ANQO2 | |
| SCHEMBL1284855 | 0.84 | KMT2A (0.59) | MTNR1A | |
| SCHEMBL761446 | 0.84 | MTNR1A (0.73) | MTNR1ANQO2 | |
| SCHEMBL9128038 | 0.84 | MTNR1A (0.63) | MTNR1ANQO2PTPN1 | |
| SCHEMBL9131472 | 0.83 | MTNR1A (0.76) | MTNR1ANQO2 | |
| SCHEMBL1567114 | 0.82 | MTNR1A (0.73) | MTNR1ANQO2PTPN1 | |
| SCHEMBL919206 | 0.82 | MTNR1A (0.64) | MTNR1APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900665-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-01 | — | — | US | disclosed |
| CN-1155562-C | Novel naphthalene compounds, process for their preparation and pharmaceutical compositions containing them | ɪά��ʵ���� | 2004-06-30 | — | — | CN | disclosed |
| US-6143789-A | ENANTIOMORPHS | ADIR ET COMPAGNIE (FR) | 2000-11-07 | — | — | US | disclosed |
| CN-1221734-A | Novel naphthalene compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-07-07 | — | — | CN | disclosed |
| EP-0919541-A1 | Naphthalene compounds, process for their preparation and their pharmaceutical compositions | ADIR ET COMPAGNIE (FR) | 1999-06-02 | — | — | EP | disclosed |
| US-5420158-A | Melatonin activity | ADIR ET COMPAGNIE (FR) | 1995-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247734-A1 | Chemically Derivatized CD4 and Uses Thereof | CD4, CD40LG, CD14 | MTNR1A 3954/4885NQO2 2256/4885PTPN1 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.